Compare KITT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | MBRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 12.7M |
| IPO Year | 2021 | 2016 |
| Metric | KITT | MBRX |
|---|---|---|
| Price | $0.62 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 457.1K | ★ 749.4K |
| Earning Date | 04-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,434,959.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 33.10 | N/A |
| 52 Week Low | $0.39 | $0.16 |
| 52 Week High | $3.65 | $7.98 |
| Indicator | KITT | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.